Ford and GM Near Financing Deal to Support First Brands Group During Bankruptcy 
Micron to Expand Memory Chip Manufacturing Capacity in Singapore Amid Global Shortage 
Shell Plc Downgraded by RBC as Market Headwinds Pressure Valuation 
Citigroup Faces Lawsuit Over Alleged Sexual Harassment by Top Wealth Executive 
BYD and Exxon Mobil Strengthen Hybrid Technology Partnership 
SoftBank Shares Surge as It Eyes Up to $30 Billion New Investment in OpenAI 
Boeing Posts Fourth-Quarter Profit on Jeppesen Sale Despite Ongoing Unit Losses 
ASML’s EUV Monopoly Powers the Global AI Chip Boom 
LVMH Investors Watch Earnings Closely as Luxury Recovery Faces New Challenges 
China Approves First Import Batch of Nvidia H200 AI Chips Amid Strategic Shift 
Trump Lawsuit Against JPMorgan Signals Rising Tensions Between Wall Street and the White House 
Zijin Mining Shares Hit Record High on $4 Billion Allied Gold Acquisition 
Noble Corporation Secures $1.3 Billion in New Contracts, Strengthening Offshore Drilling Backlog 
Trump Administration Takes Stake in USA Rare Earth to Boost U.S. Critical Minerals Supply 
Microsoft Wins Approval to Build 15 New Data Centers in Wisconsin 
Meta Faces Lawsuit Over Alleged Approval of AI Chatbots Allowing Sexual Interactions With Minors 
- Dr. Joseph Stauffer to deliver opening remarks and discuss kappa opioid receptor agonists as a novel approach to acute and chronic pain management
- Dr. Stauffer serves as co-chair and on the event’s Scientific Advisory Board
STAMFORD, Conn., May 17, 2017 -- Cara Therapeutics, Inc. (NASDAQ:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that Dr. Joseph Stauffer, Cara's Chief Medical Officer, has been selected to speak at the 17th Annual Conference on Pain Therapeutics to be held May 22-23, 2017 in London. Dr. Stauffer also serves as an event co-chair and on the conference’s Scientific Advisory Board.
On Tuesday, May 23, Dr. Stauffer will deliver opening remarks and the opening address, during which he will discuss kappa opioid receptor agonism as a new approach to managing acute and chronic pain. This discussion will highlight positive clinical trial results and human abuse liability data for CR845, the Company's first-in-class peripherally selective kappa opioid agonist. To date, results support the view that CR845 is unlikely to be recreationally abused or lead to physical dependence.
For more information on the 17th Annual Conference on Pain Therapeutics, visit https://www.smi-online.co.uk/pharmaceuticals/uk/pain-therapeutics.
About CR845
CR845 is a peripherally acting kappa opioid receptor agonist currently in development for the treatment of acute and chronic pain and pruritus. In multiple randomized, double-blind, placebo-controlled Phase 2 trials in patients undergoing laparoscopic hysterectomy or bunionectomy procedures, I.V. CR845 treatment resulted in statistically significant reductions in pain intensity and opioid-related side effects. In more than 1200 subjects dosed to date, CR845 was observed to be well-tolerated, without incurring the dysphoric and psychotomimetic side effects that have been reported with centrally acting (CNS-active) kappa opioid receptor agonists, and lacking the respiratory depression and abuse liability of mu opioid receptor agonists. Top-line data from a Phase 2b trial of Oral CR845 in chronic pain associated with osteoarthritis are expected in the second quarter of 2017.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates, led by CR845, that target the body's peripheral nervous system and have demonstrated, in Phase 2 trials, preliminary efficacy in patients with moderate-to-severe pain and pruritus without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.
MEDIA CONTACT: Annie Starr 6 Degrees 973-415-8838 [email protected] INVESTOR CONTACT: Michael Schaffzin Stern Investor Relations, Inc. 212-362-1200 [email protected]
